{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,13]],"date-time":"2026-04-13T12:10:11Z","timestamp":1776082211352,"version":"3.50.1"},"reference-count":58,"publisher":"Oxford University Press (OUP)","issue":"12","license":[{"start":{"date-parts":[[2022,3,16]],"date-time":"2022-03-16T00:00:00Z","timestamp":1647388800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,11,28]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Objectives<\/jats:title>\n                  <jats:p>To systematically review the psychometric properties of outcome measurement instruments used in ANCA-associated vasculitis (AAV).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>Medline, EMBASE, Cochrane, Scopus and Web of Science were searched from inception to 14 July 2020 for validation studies of instruments used in AAV. Following the COnsensus-based Standards for the selection of health status Measurement INstruments (COSMIN) and OMERACT frameworks, different psychometric properties (validity, reliability, responsiveness and feasibility) were summarized. Risk of bias was assessed according to the COSMIN checklist.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>From 2505 articles identified, 32 met the predefined selection criteria, providing information on 22 instruments assessing disease activity (n\u2009=\u20097), damage (n\u2009=\u20092), activity and damage (n\u2009=\u20091), health-related quality of life (HRQoL; n\u2009=\u20099) and function (n\u2009=\u20093). Most of the instruments were tested in AAV as a group or in granulomatosis with polyangiitis only.<\/jats:p>\n                  <jats:p>The BVAS, any version, the Vasculitis Damage Index (VDI) and the AAV-Patient-Reported Outcome (AAV-PRO) have been more extensively validated than the other instruments. BVAS for Wegener Granulomatosis (BVAS\/WG) has been shown to be valid for measuring disease activity [correlation with Physician global assessment (r\u2009=\u20090.90)], reliability (inter-observer intraclass correlation coefficient\u2009=\u20090.97), responsiveness and feasibility. For damage, VDI was shown to be moderately valid (correlations with BVAS version 3 at 6\u2009months r\u2009=\u20090.14, BVAS\/WG at 1\u2009year r\u2009=\u20090.40 and 5\u2009years r\u2009=\u20090.20), and feasible. For HRQoL, AAV-PRO demonstrated validity (correlations of the six AAV-PRO domains with EQ-5D-5L: \u22120.78 to \u22120.55; discrimination between active disease and remission, P\u2009&amp;lt;\u20090.0001 for all comparisons). The overall performance of instruments assessing function was low-to-moderate.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>Among the 22 outcome measurement instruments used for AAV, BVAS (any version), VDI and AAV-PRO had the strongest psychometric properties.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/rheumatology\/keac175","type":"journal-article","created":{"date-parts":[[2022,3,16]],"date-time":"2022-03-16T12:24:08Z","timestamp":1647433448000},"page":"4603-4618","source":"Crossref","is-referenced-by-count":15,"title":["Psychometric properties of outcome measurement instruments for ANCA-associated vasculitis: a systematic literature review"],"prefix":"10.1093","volume":"61","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7831-921X","authenticated-orcid":false,"given":"Alvise","family":"Berti","sequence":"first","affiliation":[{"name":"Santa Chiara Regional Hospital, APSS Trento, and Department of Cellular, Computational and Integrative Biology (CIBIO), University of Trento, Rheumatology , Trento, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gon\u00e7alo","family":"Boleto","sequence":"additional","affiliation":[{"name":"Rheumatology, Universit\u00e9 de Paris, H\u00f4pital Cochin , Paris, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter A","family":"Merkel","sequence":"additional","affiliation":[{"name":"Division of Rheumatology, Department of Medicine, Division of Epidemiology, Department of Biostatistics, Epidemiology, and Informatics, Rheumatology Division, University of Pennsylvania , Philadelphia, PA, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gunnar","family":"T\u00f3masson","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, and Centre for Rheumatology Research, University Hospital , Reykjavik, Iceland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1800-6772","authenticated-orcid":false,"given":"Sara","family":"Monti","sequence":"additional","affiliation":[{"name":"Rheumatology Department, Fondazione IRCCS Policlinico San Matteo, University of Pavia , Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0101-1580","authenticated-orcid":false,"given":"Kaitlin A","family":"Quinn","sequence":"additional","affiliation":[{"name":"Systemic Autoimmunity Branch, National Institutes of Health, NIAMS , Bethesda, MD"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Leslie C","family":"Hassett","sequence":"additional","affiliation":[{"name":"Mayo Clinic Libraries, Mayo Clinic , Rochester, MN, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4401-2551","authenticated-orcid":false,"given":"Loreto","family":"Carmona","sequence":"additional","affiliation":[{"name":"Rheumatology, Instituto de Salud Musculoesquel\u00e9tica (InMusc) , Madrid, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8899-9087","authenticated-orcid":false,"given":"Sofia","family":"Ramiro","sequence":"additional","affiliation":[{"name":"Rheumatology, Leiden University Medical Center (LUMC) , Leiden"},{"name":"Rheumatology, Zuyderland Medical Center , Heerlen, The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2022,3,16]]},"reference":[{"key":"2022112912440010600_keac175-B1","doi-asserted-by":"crossref","first-page":"525","DOI":"10.3389\/fimmu.2020.00525","article-title":"Animal models of ANCA associated vasculitis","volume":"11","author":"Shochet","year":"2020","journal-title":"Front Immunol"},{"key":"2022112912440010600_keac175-B2","doi-asserted-by":"crossref","first-page":"1583","DOI":"10.1136\/annrheumdis-2016-209133","article-title":"EULAR\/ERA-EDTA recommendations for the management of ANCA-associated vasculitis","volume":"75","author":"Yates","year":"2016","journal-title":"Ann Rheum Dis"},{"key":"2022112912440010600_keac175-B3","doi-asserted-by":"crossref","first-page":"1480","DOI":"10.3899\/jrheum.110276","article-title":"The OMERACT core set of outcome measures for use in clinical trials of ANCA-associated vasculitis","volume":"38","author":"Merkel","year":"2011","journal-title":"J Rheumatol"},{"key":"2022112912440010600_keac175-B4","doi-asserted-by":"crossref","first-page":"593","DOI":"10.3899\/jrheum.131248","article-title":"Current status of outcome measure development in vasculitis","volume":"41","author":"Merkel","year":"2014","journal-title":"J Rheumatol"},{"key":"2022112912440010600_keac175-B5","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.3899\/jrheum.181218","article-title":"Instrument selection using the OMERACT filter 2.1: the OMERACT methodology","volume":"46","author":"Beaton","year":"2019","journal-title":"J Rheumatol"},{"key":"2022112912440010600_keac175-B6","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1007\/s11136-010-9606-8","article-title":"The COSMIN checklist for assessing the methodological quality of studies on measurement properties of health status measurement instruments: an international Delphi study","volume":"19","author":"Mokkink","year":"2010","journal-title":"Qual Life Res"},{"key":"2022112912440010600_keac175-B7","doi-asserted-by":"crossref","first-page":"1314","DOI":"10.1016\/j.semarthrit.2020.09.010","article-title":"Use and reporting of outcome measures in randomized trials for anti-neutrophil cytoplasmic antibody-associated vasculitis: a systematic literature review of randomized trials","volume":"50","author":"Monti","year":"2020","journal-title":"Semin Arthritis Rheum"},{"key":"2022112912440010600_keac175-B8","first-page":"910","article-title":"The EULAR Outcome Measures Library: development and an example from a systematic review for systemic lupus erythematous instruments","volume":"33","author":"Castrejon","year":"2015","journal-title":"Clin Exp Rheumatol"},{"key":"2022112912440010600_keac175-B9","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1007\/s11136-011-9960-1","article-title":"Rating the methodological quality in systematic reviews of studies on measurement properties: a scoring system for the COSMIN checklist","volume":"21","author":"Terwee","year":"2012","journal-title":"Qual Life Res"},{"key":"2022112912440010600_keac175-B10","doi-asserted-by":"crossref","first-page":"e1000100","DOI":"10.1371\/journal.pmed.1000100","article-title":"The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration","volume":"6","author":"Liberati","year":"2009","journal-title":"PLoS Med"},{"key":"2022112912440010600_keac175-B11","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1002\/lary.23737","article-title":"A disease activity score for ENT involvement in granulomatosis with polyangiitis (Wegener\u2019s)","volume":"123","author":"Del Pero","year":"2013","journal-title":"Laryngoscope"},{"key":"2022112912440010600_keac175-B12","doi-asserted-by":"crossref","DOI":"10.1002\/jcla.23022","article-title":"Multivariable index for assessing the activity and predicting all-cause mortality in antineutrophil cytoplasmic antibody-associated vasculitis","volume":"34","author":"Kim","year":"2020","journal-title":"J Clin Lab Anal"},{"key":"2022112912440010600_keac175-B13","doi-asserted-by":"crossref","first-page":"17","DOI":"10.2147\/PROM.S144992","article-title":"Health-related quality of life in ANCA-associated vasculitis and item generation for a disease-specific patient-reported outcome measure","volume":"9","author":"Robson","year":"2018","journal-title":"Patient Relat Outcome Meas"},{"key":"2022112912440010600_keac175-B14","doi-asserted-by":"crossref","first-page":"1296","DOI":"10.1002\/art.23017","article-title":"Development and initial evaluation of a measure of self-management for adults with antineutrophil cytoplasmic antibody-associated small-vessel vasculitis","volume":"57","author":"Thorpe","year":"2007","journal-title":"Arthritis Rheum"},{"key":"2022112912440010600_keac175-B15","doi-asserted-by":"crossref","first-page":"2365","DOI":"10.1002\/1529-0131(199911)42:11<2365::AID-ANR15>3.0.CO;2-M","article-title":"Validity of a vasculitis activity index for systemic necrotizing vasculitis","volume":"42","author":"Whiting-O\u2019Keefe","year":"1999","journal-title":"Arthritis Rheum"},{"key":"2022112912440010600_keac175-B16","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1007\/s10067-015-2921-2","article-title":"Patient-reported outcomes in ANCA-associated vasculitis. A comparison between Birmingham Vasculitis Activity Score and routine assessment of patient index data 3","volume":"35","author":"Annapureddy","year":"2016","journal-title":"Clin Rheumatol"},{"key":"2022112912440010600_keac175-B17","first-page":"31","article-title":"Development and validation of a disease extent index for Wegener\u2019s granulomatosis","volume":"55","author":"de Groot","year":"2001","journal-title":"Clin Nephrol"},{"key":"2022112912440010600_keac175-B18","article-title":"Intra- and inter-rater reliability of endonasal activity estimation in granulomatosis with polyangiitis (Wegener\u2019s)","volume":"30","author":"Garske","year":"2012","journal-title":"Clin Exp Rheumatol"},{"key":"2022112912440010600_keac175-B19","article-title":"Intra- and inter-rater reliability of the modified ENT assessment score (ENTAS 2) in granulomatosis with polyangiitis: a prospective randomised trial","volume":"35","author":"Decker","year":"2017","journal-title":"Clin Exp Rheumatol"},{"key":"2022112912440010600_keac175-B20","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.3899\/jrheum.111030","article-title":"Assessing the performance of the Birmingham vasculitis activity score at diagnosis for Children with antineutrophil cytoplasmic antibody-associated vasculitis in a registry for childhood vasculitis (ARChiVe)","volume":"39","author":"Morishita","year":"2012","journal-title":"J Rheumatol"},{"key":"2022112912440010600_keac175-B21","doi-asserted-by":"crossref","first-page":"2168","DOI":"10.1002\/art.21117","article-title":"Damage caused by Wegener\u2019s granulomatosis and its treatment: prospective data from the Wegener\u2019s Granulomatosis Etanercept Trial (WGET)","volume":"52","author":"Seo","year":"2005","journal-title":"Arthritis Rheum"},{"key":"2022112912440010600_keac175-B22","doi-asserted-by":"crossref","first-page":"112","DOI":"10.3109\/14397595.2013.852836","article-title":"Long-term damage assessment in patients with microscopic polyangiitis and renal-limited vasculitis using the Vasculitis Damage Index","volume":"24","author":"Itabashi","year":"2014","journal-title":"Mod Rheumatol"},{"key":"2022112912440010600_keac175-B23","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1093\/rheumatology\/ker280","article-title":"Value of ANCA measurements during remission to predict a relapse of ANCA-associated vasculitis-a meta-analysis","volume":"51","author":"Tomasson","year":"2012","journal-title":"Rheumatology (Oxford)"},{"key":"2022112912440010600_keac175-B24","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1007\/s10286-016-0364-8","article-title":"Assessment of autonomic function in a cohort of patients with ANCA-associated vasculitis","volume":"26","author":"Moog","year":"2016","journal-title":"Clin Auton Res"},{"key":"2022112912440010600_keac175-B25","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1002\/art.11471","article-title":"Investigation of quality of life, mood, pain, disability, and disease status in primary systemic vasculitis","volume":"49","author":"Koutantji","year":"2003","journal-title":"Arthritis Rheum"},{"key":"2022112912440010600_keac175-B26","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1097\/RHU.0000000000000713","article-title":"Overall disability sum score for clinical assessment of neurological involvement in eosinophilic granulomatosis with polyangiitis","volume":"24","author":"Padoan","year":"2018","journal-title":"J Clin Rheumatol"},{"key":"2022112912440010600_keac175-B27","doi-asserted-by":"crossref","first-page":"2081","DOI":"10.3899\/jrheum.100167","article-title":"Impaired health-related quality of life in patients treated for Wegener\u2019s granulomatosis","volume":"37","author":"Faurschou","year":"2010","journal-title":"J Rheumatol"},{"key":"2022112912440010600_keac175-B28","doi-asserted-by":"crossref","first-page":"1332","DOI":"10.1002\/acr.22827","article-title":"Physical fatigue, fitness, and muscle function in patients with antineutrophil cytoplasmic antibody\u2013associated vasculitis","volume":"68","author":"McClean","year":"2016","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"2022112912440010600_keac175-B29","doi-asserted-by":"crossref","first-page":"1785","DOI":"10.3899\/jrheum.190828","article-title":"Utility of the brief illness perception questionnaire to monitor patient beliefs in systemic vasculitis","volume":"47","author":"Schwartz","year":"2020","journal-title":"J Rheumatol"},{"key":"2022112912440010600_keac175-B30","doi-asserted-by":"crossref","first-page":"1835","DOI":"10.1002\/acr.22069","article-title":"Illness perceptions and fatigue in systemic vasculitis","volume":"65","author":"Grayson","year":"2013","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"2022112912440010600_keac175-B31","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1093\/rheumatology\/keq400","article-title":"A cross-sectional study of the Birmingham Vasculitis Activity Score version 3 in systemic vasculitis","volume":"50","author":"Suppiah","year":"2011","journal-title":"Rheumatology (Oxford)"},{"key":"2022112912440010600_keac175-B32","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1136\/ard.2009.122952","article-title":"Measurement of damage in systemic vasculitis: a comparison of the Vasculitis Damage Index with the Combined Damage Assessment Index","volume":"70","author":"Suppiah","year":"2011","journal-title":"Ann Rheum Dis"},{"key":"2022112912440010600_keac175-B33","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1136\/annrheumdis-2013-203927","article-title":"Damage in the ANCA-associated vasculitides: long-term data from the European vasculitis study group (EUVAS) therapeutic trials","volume":"74","author":"Robson","year":"2015","journal-title":"Ann Rheum Dis"},{"key":"2022112912440010600_keac175-B34","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1056\/NEJMoa1213277","article-title":"Efficacy of remission-induction regimens for ANCA-associated vasculitis","volume":"369","author":"Specks","year":"2013","journal-title":"N Engl J Med"},{"key":"2022112912440010600_keac175-B35","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1007\/s11883-013-0315-y","article-title":"The cholesterol emboli syndrome in atherosclerosis","volume":"15","author":"Quinones","year":"2013","journal-title":"Curr Atheroscler Rep"},{"key":"2022112912440010600_keac175-B36","doi-asserted-by":"crossref","first-page":"304","DOI":"10.3109\/14397595.2013.854075","article-title":"Assessment of the Birmingham Vasculitis Activity Score in patients with MPO-ANCA-associated vasculitis: sub-analysis from a study by the Japanese Study Group for MPO-ANCA-associated vasculitis","volume":"24","author":"Yumura","year":"2014","journal-title":"Mod Rheumatol"},{"key":"2022112912440010600_keac175-B37","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1093\/rheumatology\/kem029","article-title":"Elevated relapse rate under oral methotrexate versus leflunomide for maintenance of remission in Wegener\u2019s granulomatosis","volume":"46","author":"Metzler","year":"2007","journal-title":"Rheumatology (Oxford)"},{"key":"2022112912440010600_keac175-B38","doi-asserted-by":"crossref","first-page":"928","DOI":"10.3899\/jrheum.171405","article-title":"Feasibility and construct validation of the patient reported outcomes measurement information system in systemic vasculitis","volume":"46","author":"Tomasson","year":"2019","journal-title":"J Rheumatol"},{"key":"2022112912440010600_keac175-B39","doi-asserted-by":"crossref","first-page":"1342","DOI":"10.1136\/annrheumdis-2012-201981","article-title":"Serum proteins reflecting inflammation, injury and repair as biomarkers of disease activity in ANCA-associated vasculitis","volume":"72","author":"Monach","year":"2013","journal-title":"Ann Rheum Dis"},{"key":"2022112912440010600_keac175-B40","first-page":"1157","article-title":"Validation of the ANCA-associated vasculitis patient-reported outcomes (AAV-PRO) questionnaire","volume":"77","author":"Robson","year":"2018","journal-title":"Ann Rheum Dis"},{"key":"2022112912440010600_keac175-B41","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1002\/art.23707","article-title":"Assessment of the item selection and weighting in the Birmingham vasculitis activity score for Wegener\u2019s granulomatosis","volume":"59","author":"Mahr","year":"2008","journal-title":"Arthritis Rheum"},{"key":"2022112912440010600_keac175-B42","doi-asserted-by":"crossref","first-page":"912","DOI":"10.1002\/1529-0131(200104)44:4<912::AID-ANR148>3.0.CO;2-5","article-title":"A disease-specific activity index for Wegener\u2019s granulomatosis: modification of the Birmingham Vasculitis Activity Score. International Network for the Study of the Systemic Vasculitides (INSSYS)","volume":"44","author":"Stone","year":"2001","journal-title":"Arthritis Rheum"},{"key":"2022112912440010600_keac175-B43","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1002\/acr.20649","article-title":"Assessment of health-related quality of life as an outcome measure in granulomatosis with polyangiitis (Wegener\u2019s)","volume":"64","author":"Tomasson","year":"2012","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"2022112912440010600_keac175-B44","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1002\/art.38248","article-title":"Brief report: the value of a patient global assessment of disease activity in granulomatosis with polyangiitis (Wegener\u2019s)","volume":"66","author":"Tomasson","year":"2014","journal-title":"Arthritis Rheumatol"},{"key":"2022112912440010600_keac175-B45","first-page":"789","article-title":"The dimensions of health outcomes: the health assessment questionnaire, disability and pain scales","volume":"9","author":"Fries","year":"1982","journal-title":"J Rheumatol"},{"key":"2022112912440010600_keac175-B46","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.3899\/jrheum.181073","article-title":"Updating OMERACT core set of domains for ANCA-associated vasculitis: patient perspective using the international classification of function, disability, and health","volume":"46","author":"Milman","year":"2019","journal-title":"J Rheumatol"},{"key":"2022112912440010600_keac175-B47","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1136\/ard.2008.097758","article-title":"Comparison of disease activity measures for antineutrophil cytoplasmic autoantibody (ANCA)- associated vasculitis","volume":"68","author":"Merkel","year":"2009","journal-title":"Ann Rheum Dis"},{"key":"2022112912440010600_keac175-B48","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1007\/s00405-010-1421-x","article-title":"Long-term damage to the ENT system in Wegener\u2019s granulomatosis","volume":"268","author":"Del Pero","year":"2011","journal-title":"Eur Arch Otorhinolaryngol"},{"key":"2022112912440010600_keac175-B49","first-page":"2390","article-title":"Defining response in systemic lupus erythematosus: a study by the Systemic Lupus International Collaborating Clinics group","volume":"31","author":"Wollaston","year":"2004","journal-title":"J Rheumatol"},{"key":"2022112912440010600_keac175-B50","first-page":"1357","article-title":"The future of damage assessment in vasculitis","volume":"34","author":"Seo","year":"2007","journal-title":"J Rheumatol"},{"key":"2022112912440010600_keac175-B51","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1097\/00005650-199206000-00002","article-title":"The MOS 36-item short-form health survey (Sf-36): i. conceptual framework and item selection","volume":"30","author":"Ware","year":"1992","journal-title":"Med Care"},{"key":"2022112912440010600_keac175-B52","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1186\/1477-7525-7-25","article-title":"The health-related quality of life in rheumatoid arthritis, ankylosing spondylitis, and psoriatic arthritis: a comparison with a selected sample of healthy people","volume":"7","author":"Salaffi","year":"2009","journal-title":"Health Qual Life Outcomes"},{"key":"2022112912440010600_keac175-B53","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1177\/1120672120901693","article-title":"Vision-related and health-related quality of life in patients with giant cell arteritis","volume":"31","author":"N\u00ed Mh\u00e9al\u00f3id","year":"2020","journal-title":"Eur J Ophthalmol"},{"key":"2022112912440010600_keac175-B54","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1002\/art.1780400222","article-title":"Development and initial validation of the Vasculitis Damage Index for the standardized clinical assessment of damage in the systemic vasculitides","volume":"40","author":"Exley","year":"1997","journal-title":"Arthritis Rheum"},{"key":"2022112912440010600_keac175-B55","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1093\/rheumatology\/37.1.57","article-title":"Examination of disease severity in systemic vasculitis from the novel perspective of damage using the vasculitis damage index (VDI)","volume":"37","author":"Exley","year":"1998","journal-title":"Br J Rheumatol"},{"key":"2022112912440010600_keac175-B56","first-page":"671","article-title":"Birmingham Vasculitis Activity Score (BVAS) in systemic necrotizing vasculitis","volume":"87","author":"Luqmani","year":"1994","journal-title":"QJM"},{"key":"2022112912440010600_keac175-B57","doi-asserted-by":"crossref","first-page":"1827","DOI":"10.1136\/ard.2008.101279","article-title":"Modification and validation of the Birmingham Vasculitis Activity Score (version 3)","volume":"68","author":"Mukhtyar","year":"2009","journal-title":"Ann Rheum Dis"},{"key":"2022112912440010600_keac175-B58","doi-asserted-by":"crossref","first-page":"1628","DOI":"10.1136\/annrheumdis-2012-202111","article-title":"Disease activity assessment in childhood vasculitis: development and preliminary validation of the Paediatric Vasculitis Activity Score (PVAS)","volume":"72","author":"Dolezalova","year":"2013","journal-title":"Ann Rheum Dis"}],"container-title":["Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/rheumatology\/advance-article-pdf\/doi\/10.1093\/rheumatology\/keac175\/45641476\/keac175.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/rheumatology\/article-pdf\/61\/12\/4603\/47386035\/keac175.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/rheumatology\/article-pdf\/61\/12\/4603\/47386035\/keac175.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,29]],"date-time":"2022-11-29T12:47:12Z","timestamp":1669726032000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/rheumatology\/article\/61\/12\/4603\/6549520"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3,16]]},"references-count":58,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2022,3,16]]},"published-print":{"date-parts":[[2022,11,28]]}},"URL":"https:\/\/doi.org\/10.1093\/rheumatology\/keac175","relation":{},"ISSN":["1462-0324","1462-0332"],"issn-type":[{"value":"1462-0324","type":"print"},{"value":"1462-0332","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2022,12,1]]},"published":{"date-parts":[[2022,3,16]]}}}